Citation Impact
Citing Papers
Review article: the global emergence of Helicobacter pylori antibiotic resistance
2015
Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity
2013 StandoutNobel
Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity
2011
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
Rapid detection of Mycobacterium tuberculosis in sputum with a solvatochromic trehalose probe
2018 StandoutNobel
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
2012 Standout
Therapeutic Options for Diabetic Foot Infections
2010
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
The Helicobacter pylori Resistance Rate to Clarithromycin in Iran
2014
Susceptibility of Helicobacter pylori to Levofloxacin and Rifampicin in Israel
2015
Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit
2009
Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial
2010
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications
2015 Standout
Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996–2001). Description of new mutations in the rpoB gene and review of the literature
2003
“Rescue” regimens after Helicobacter pylori treatment failure
2008
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens
2008
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
2015
Diabetic Foot Ulcers and Their Recurrence
2017 Standout
A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections
2008
Isavuconazonium: First Global Approval
2015
Helicobacter pylori and antibiotic resistance
2007
In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults
2002
Natural products: An evolving role in future drug discovery
2011 Standout
Randomized study of two "rescue" therapies for helicobacter pylori-infected patients after failure of standard triple therapies
2001
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases
2014
Community-associated meticillin-resistant Staphylococcus aureus
2010
High Helicobacter pylori Resistance to Metronidazole but Zero or Low Resistance to Clarithromycin, Levofloxacin, and Other Antibiotics in Malaysia
2011
High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection
2014
Nanotechnology as a therapeutic tool to combat microbial resistance
2013 Standout
Skin and Soft‐Tissue Infections Caused by Community‐Acquired Methicillin‐ResistantStaphylococcus aureus
2008
Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo
2012 Standout
The effectiveness of rifabutin triple therapy for patients with difficult‐to‐eradicate Helicobacter pylori in clinical practice
2007
The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials
2008
Waves of resistance: Staphylococcus aureus in the antibiotic era
2009 Standout
Helicobacter pylori ‘rescue’ regimen when proton pump inhibitor‐based triple therapies fail
2002
What is in the pipeline for Gram-negative pathogens?
2008
Synergism between natural products and antibiotics against infectious diseases
2008 Standout
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
2008 Standout
Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole
2010
Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model
2005
Antibiotic resistance and its cost: is it possible to reverse resistance?
2010 Standout
Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998–2002
2003
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods
2016
Helicobacter pylori-associated diseases
2002
Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin‐susceptible and clarithromycin‐resistant Helicobacter pylori strains in gastric biopsies from children
2002
Meta-analysis of Randomized Controlled Trials of Vancomycin for the Treatment of Patients With Gram-Positive Infections: Focus on the Study Design
2012
Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts
2003
Role of Folate Antagonists in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection
2008
Helicobacter pylori eradication and gastric ulcer healing — comparison of three pantoprazole‐based triple therapies
2003
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy ofHelicobacter pyloriinfection
2009
Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution?
2005
The Impact of the Gut Microbiota on Human Health: An Integrative View
2012 Standout
Respiratory Diseases and <i>Helicobacter pylori</i> Infection: Is There a Link?
2006
Rifampicin resistance and its fitness cost in Enterococcus faecium
2004
Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions
2018 Standout
The challenge of emerging and re-emerging infectious diseases
2004 StandoutNature
Rabeprazole: the role of proton pump inhibitors inHelicobacter pylorieradication
2005
Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany
2009
Novel β-lactam antibiotics and inhibitor combinations
2008
H pylori antibiotic resistance: prevalence, importance, and advances in testing
2004 Standout
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
2019
New Rules for Clinical Trials of Patients With Acute Bacterial Skin and Skin-Structure Infections: Do Not Let the Perfect Be the Enemy of the Good
2011
Helicobacter pyloriInfection
2002 Standout
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections
2012
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
2001
High rate of post‐therapeutic resistance after failure of macrolide–nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second‐line therapies in a randomized study
2002
Clinical management of Staphylococcus aureus bacteraemia
2011
High efficacy of 1‐week doxycycline‐ and amoxicillin‐based quadruple regimen in a culture‐guided, third‐line treatment approach for Helicobacter pylori infection
2004
Third‐line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures
2006
Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin
2004
Review article: rifabutin in the treatment of refractoryHelicobacter pyloriinfection
2011
Empirical rescue therapy after Helicobacter pylori treatment failure: a 10‐year single‐centre study of 500 patients
2007
Review article: the treatment of refractory Helicobacter pylori infection
2003
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections
2013
Helicobacter pylori first‐line treatment and rescue options in patients allergic to penicillin
2005
Molecular testing for antibiotic resistance in Helicobacter pylori
2002
Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection
2009
Combination Therapy for Mucormycosis: Why, What, and How?
2012
Levofloxacin/amoxicillin-based schemesvsquadruple therapy forHelicobacter pylorieradication in second-line
2012
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report
2006 Standout
Update on therapeutic options for Helicobacter pylori-related diseases
2005
How antibiotics kill bacteria: from targets to networks
2010 Standout
The Biosynthetic Logic of Polyketide Diversity
2009 Standout
The human skin microbiome
2018 Standout
In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium Species
2008
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
23S rRNA base pair 2057–2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A→G
2005 StandoutNobel
Basis for the Management of Drug-Resistant Helicobacter pylori Infection
2004
Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities
2011
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Roles of FrxA and RdxA Nitroreductases of Helicobacter pylori in Susceptibility and Resistance to Metronidazole
2001
Comparison of Fluorescent In Situ Hybridization and Conventional Culturing for Detection of Helicobacter pylori in Gastric Biopsy Specimens
2001
Helicobacter pyloriDetection and Antimicrobial Susceptibility Testing
2007
Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations
2012
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Is H elicobacter pylori antibiotic resistance surveillance needed and how can it be delivered?
2012
High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis
2013
The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America
2006 Standout
Multilocus Sequence Typing of Total-Genome-Sequenced Bacteria
2012 Standout
Pathogenesis ofHelicobacter pyloriInfection
2006 Standout
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
RifamycinMode of Action, Resistance, and Biosynthesis
2005
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus
2013
Three Decades of β-Lactamase Inhibitors
2010 Standout
Characterization of an In Vitro-Selected Amoxicillin-Resistant Strain of Helicobacter pylori
2000
Daptomycin: The role of high-dose and combination therapy for Gram-positive infections
2013
Antibiotic Susceptibilities of Anaplasma ( Ehrlichia ) phagocytophilum Strains from Various Geographic Areas in the United States
2002
Ceftobiprole: An Extended-Spectrum Anti–Methicillin-Resistant Staphylococcus aureus Cephalosporin
2008
Specific mutations in theMycobacterium tuberculosis rpoBgene are associated with increaseddnaE2expression
2007
CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections
2012
Singleand Double Mutations in gyrA but Not in gyrB AreAssociated with Low- and High-Level Fluoroquinolone Resistance in Helicobacterpylori
2003
2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infectionsa
2012 Standout
Rapid Detection of Point Mutations in the gyrA Gene of Helicobacter pylori Conferring Resistance to Ciprofloxacin by a Fluorescence Resonance Energy Transfer-Based Real-Time PCR Approach
2004
Enzymic colorimetry-based DNA chip: a rapid and accurate assay for detecting mutations for clarithromycin resistance in the 23S rRNA gene of Helicobacter pylori
2009
Ceftobiprole: drug evaluation and place in therapy
2019
2015 ESC Guidelines for the management of infective endocarditis
2015 Standout
Upregulation of the Phthiocerol Dimycocerosate Biosynthetic Pathway by Rifampin-Resistant,rpoBMutant Mycobacterium tuberculosis
2012 StandoutNobel
Community-Associated Methicillin-ResistantStaphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic
2010 Standout
Isavuconazole: A New and Promising Antifungal Triazole for the Treatment of Invasive Fungal Infections
2008
Catalytic Asymmetric Protonation of Silyl Ketene Imines
2013 StandoutNobel
Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori
2001
Rifampicin Resistance in Tuberculosis Outbreak, London, England
2005
Characterization of rpoB Mutations in Rifampin-Resistant Clinical Isolates of Mycobacterium tuberculosis from Turkey by DNA Sequencing and Line Probe Assay
2002
Mutations in the rpoB Gene of Multidrug-Resistant Mycobacterium tuberculosis Isolates from China
2003
In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds
2013
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship
2006 Standout
Rifabutin‐based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens
2000
Works of M. Heep being referenced
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus
2006
Pharmacokinetics, Safety and Tolerability Results of a Dose Escalation Study of Isavuconazole in Neutropenic Patients
2008
In VitroAntifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries
2009
Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORESM database
2013
Detection of Rifabutin Resistance and Association of rpoB Mutations with Resistance to Four Rifamycin Derivatives in Helicobacter pylori
2002
Rifabutin-based Triple Therapy After Failure of Helicobacter pylori Eradication Treatment
2000
Secondary Resistance Among 554 Isolates of Helicobacter pylori After Failure of Therapy
2000
Daptomycin for the treatment of infective endocarditis: results from a European registry
2012
Mutations in the Beginning of the rpoB Gene Can Induce Resistance to Rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis
2000
Transport and Storage of Fresh and Frozen Gastric Biopsy Specimens for Optimal Recovery of Helicobacter pylori
1999
Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557
2009
Mutations at Four Distinct Regions of the rpoB Gene Can Reduce the Susceptibility of Helicobacter pylori to Rifamycins
2000
Frequency of rpoB Mutations Inside and Outside the Cluster I Region in Rifampin-Resistant Clinical Mycobacterium tuberculosis Isolates
2001
Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy
2007
P1676 Evaluation of isavuconazole (BAL8557/BAL4815) Etest compared to broth microdilution antifungal susceptibility testing against quality control strains and fluconazole-susceptible clinical Candida isolates
2007
Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers
2005
P987 Steady-state bioavailability of oral isavuconazole in healthy volunteers
2007
P1675 QTc measurements during a placebo- and actively controlled multiple dose study of two different dosing regimens of isavuconazole
2007
Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers
2005
Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria
2007
Rifampin and Rifabutin Resistance Mechanism in Helicobacter pylori
1999